AR054526A1 - Metodo para tartar pacientes con una vacuna de glicoproteina mucinosa (muc-1) - Google Patents

Metodo para tartar pacientes con una vacuna de glicoproteina mucinosa (muc-1)

Info

Publication number
AR054526A1
AR054526A1 ARP060102795A AR054526A1 AR 054526 A1 AR054526 A1 AR 054526A1 AR P060102795 A ARP060102795 A AR P060102795A AR 054526 A1 AR054526 A1 AR 054526A1
Authority
AR
Argentina
Prior art keywords
muc
amino acid
acid sequence
glicoprotein
tarting
Prior art date
Application number
Other languages
English (en)
Inventor
Michael B Longenecker
Original Assignee
Biomira Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomira Inc filed Critical Biomira Inc
Publication of AR054526A1 publication Critical patent/AR054526A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1735—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0012—Lipids; Lipoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4725—Mucins, e.g. human intestinal mucin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)

Abstract

Método para tratar un individuo que está afectado por un cáncer, tal como cáncer de células pulmonares no pequenas o cáncer de prostata, que comprende administrarle a dicho individuo una formulacion basada en MUC-1. La formulacion puede ser una formulacion de vacuna liposomica basada en MUC-1. Reivindicacion 1: Un método para tratar un sujeto con cáncer de células pulmonares no pequenas caracterizado porque comprende: a) seleccionar para el tratamiento un sujeto que tiene cáncer de células pulmonares no pequenas; y b) administrarle a dicho sujeto, por un período de tiempo, una formulacion basada en MUC-1, donde la formulacion comprende: i) un liposoma; y ii) al menos un polipéptido que comprende una secuencia de aminoácidos seleccionada del grupo que consiste en la secuencia de aminoácidos de SEQ ID Ns1, una variante con actividad inmunologica de la secuencia de aminoácidos de SEW ID Ns 1, la secuencia de aminoácidos de SEQ ID Ns 2, y una variante con actividad inmunologica de la secuencia de aminoácidos de SEQ ID Ns 2.
ARP060102795 2005-06-28 2006-06-28 Metodo para tartar pacientes con una vacuna de glicoproteina mucinosa (muc-1) AR054526A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69423305P 2005-06-28 2005-06-28

Publications (1)

Publication Number Publication Date
AR054526A1 true AR054526A1 (es) 2007-06-27

Family

ID=37708986

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102795 AR054526A1 (es) 2005-06-28 2006-06-28 Metodo para tartar pacientes con una vacuna de glicoproteina mucinosa (muc-1)

Country Status (16)

Country Link
US (3) US8871250B2 (es)
EP (2) EP2366400B1 (es)
JP (3) JP5364371B2 (es)
CN (2) CN105194650A (es)
AR (1) AR054526A1 (es)
AU (1) AU2006274651B2 (es)
BR (1) BRPI0613510A2 (es)
CA (1) CA2613327A1 (es)
DK (2) DK1896051T3 (es)
ES (2) ES2526344T3 (es)
HK (1) HK1219417A1 (es)
HU (1) HUE026490T2 (es)
PL (2) PL2366400T3 (es)
PT (2) PT2366400E (es)
TW (2) TWI511738B (es)
WO (1) WO2007015171A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE343375T1 (de) 2001-03-27 2006-11-15 Biomira Inc Impfstoff zur modulation zwischen t1 und t2 immunantworten
JP4527407B2 (ja) * 2002-04-15 2010-08-18 オンコサイレオン インコーポレーテッド ワクチンとしての合成グリコリポペプチド
TW201204410A (en) * 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
US8871250B2 (en) 2005-06-28 2014-10-28 Oncothyreon Inc. Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine
US20120034294A1 (en) * 2008-12-17 2012-02-09 Oncothyreon, Inc. Method of making small liposomes
KR20110138354A (ko) * 2009-03-24 2011-12-27 트랜스진 에스.에이. 환자를 모니터링하기 위한 바이오마커
PL2419728T3 (pl) * 2009-04-17 2014-05-30 Transgene Sa Biomarker do monitorowania pacjentów
GB0910751D0 (en) 2009-06-23 2009-08-05 Procure Therapeutics Ltd Prostate cancer vaccine
US9261512B2 (en) 2009-07-10 2016-02-16 Transgene, S.A. Biomarker for treating cancer patients
EP2560989B1 (en) 2010-04-19 2017-03-22 Sumitomo Bakelite Co., Ltd. Cancer-related glycopeptide epitopes, antibodies and methods of use
CN105193724A (zh) 2011-02-24 2015-12-30 肿瘤防护公司 含有佐剂的以muc1 为基础的糖脂肽疫苗
SG11201509357WA (en) * 2013-05-14 2015-12-30 Merck Patent Gmbh Method of treating lung cancer by vaccination with muc-1 lipopeptide
KR20160043103A (ko) * 2013-08-21 2016-04-20 큐어백 아게 전립선암 치료를 위한 조성물 및 백신
KR101630911B1 (ko) 2013-12-26 2016-06-15 주식회사 포스코 연주압연방법
US11433143B2 (en) * 2017-05-18 2022-09-06 The Regents Of The University Of California Nano-enabled immunotherapy in cancer
CN112190688A (zh) * 2020-09-09 2021-01-08 广州医科大学附属第一医院（广州呼吸中心） 粘蛋白muc1在制备具有延缓肺衰老功效的药物中的应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US5019383A (en) 1981-01-09 1991-05-28 New York Blood Center, Inc. Fatty acid carriers for synthetic peptides
ZA831547B (en) 1982-03-15 1984-10-31 New York Blood Center Inc Fatty acid carriers for synthetic vaccines
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5837249A (en) 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
DE3683688D1 (de) 1985-04-19 1992-03-12 Wistar Inst Impfstoff fuer die erzeugung einer gegen ein virus schuetzenden immunogenen t-zellen-antwort.
IT1213029B (it) 1986-01-30 1989-12-07 Bracco Ind Chimica Spa Chelati di ioni metallici paramagnetici.
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4868155A (en) 1987-10-05 1989-09-19 Merck & Co., Inc. Dipeptidyl 4-0-,6-0-acyl-2-amino-2-deoxy-D-glucose compositions and methods of use in AIDS-immunocompromised human hosts
US5871746A (en) 1990-12-18 1999-02-16 Institut National De La Sainte Et De La Recherche Medicale (Inserm) Cytotoxic T lymphocyte-inducing lipopeptides and use as vaccines
FR2670787B1 (fr) 1990-12-18 1995-06-23 Pasteur Institut Lipopeptides inducteurs des lymphocytes t cytotoxiques et utilisation comme vaccins.
US5993823A (en) 1990-12-18 1999-11-30 Institut Pasteur De Lille Cytotoxic T lymphocyte-inducing lipopeptides and methods of use
ES2044781B1 (es) 1992-04-14 1994-10-01 Menarini Lab Procedimiento para la preparacion de nuevas amidas con accion inhibidora de la fosfolipasa a2
WO1993022343A1 (en) 1992-05-01 1993-11-11 The Rockfeller University Multiple antigen peptide system having adjuvant properties and vaccines prepared therefrom
US5744144A (en) 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
WO1995027505A1 (en) 1994-04-12 1995-10-19 Biomira, Inc. Cellular immune response-specific antigens and uses therefor
CA2189356A1 (en) 1994-05-02 1995-11-09 Ting Chi Wong Process for preparation of glycosides of tumor-associated carbohydrate antigens
WO1996040236A1 (en) 1995-06-07 1996-12-19 National Jewish Center For Immunology And Respiratory Medicine Isolated formylated bacterial peptides, nucleic acid molecules and uses thereof
AUPN568095A0 (en) 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
CA2249395A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Conjugated mucin peptide vaccines
CA2252055C (en) 1996-04-11 2007-01-16 The University Of British Columbia Fusogenic liposomes
US5910306A (en) 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
EP2341072A3 (en) * 1997-05-08 2013-10-30 Oncothyreon Inc. Method for Generating Activated T-Cells and Antigen-Pulsed Antigen-Presenting Cells
FR2774687B1 (fr) 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
FR2776926B1 (fr) 1998-04-07 2003-10-24 Inst Nat Sante Rech Med Lipopeptides inducteurs de cytotoxicite t lymphocytaire portant au moins un epitope t auxiliaire, et leurs utilisations pour la vaccination
US20020051813A1 (en) 1999-01-15 2002-05-02 Lawrence Boni Lipomatrix preparation
WO2001012217A1 (en) 1999-08-18 2001-02-22 Altarex Corp. Therapeutic antibody against muc-1 antigen and methods for their use
US7147850B2 (en) * 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
ATE338121T1 (de) * 1999-09-08 2006-09-15 Transgene Sa Von muc-1 abgeleitete peptide
AU780577B2 (en) 1999-11-15 2005-04-07 Oncothyreon Inc. Synthetic Lipid-A analogs and uses thereof
AU4871001A (en) 2000-03-24 2001-10-03 Biomira Inc Lipopeptide adjuvants
EP1182210A1 (en) 2000-08-17 2002-02-27 BASTERT, Gunter, Prof.Dr.med.Dr.h.c. Epitopes of tumor-associated MUC1 antigen
WO2002043699A2 (en) 2000-12-01 2002-06-06 Biomira, Inc. Preparation of large liposomes by infusion into peg
ATE343375T1 (de) 2001-03-27 2006-11-15 Biomira Inc Impfstoff zur modulation zwischen t1 und t2 immunantworten
EP1458242A4 (en) 2001-07-06 2006-06-07 Sloan Kettering Inst Cancer COMPREHENSIVE CONJUGATED VACCINE AGAINST CANCER
JP4527407B2 (ja) 2002-04-15 2010-08-18 オンコサイレオン インコーポレーテッド ワクチンとしての合成グリコリポペプチド
CA2485253C (en) 2002-05-09 2012-07-10 Biomira, Inc. Lipid a and other carbohydrate ligand analogs
TW201204410A (en) 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
US8871250B2 (en) 2005-06-28 2014-10-28 Oncothyreon Inc. Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine

Also Published As

Publication number Publication date
JP2016014046A (ja) 2016-01-28
AU2006274651A1 (en) 2007-02-08
US8871250B2 (en) 2014-10-28
JP5858894B2 (ja) 2016-02-10
EP1896051B1 (en) 2014-10-15
AU2006274651B2 (en) 2012-09-27
HK1219417A1 (zh) 2017-04-07
US20150071990A1 (en) 2015-03-12
DK1896051T3 (en) 2015-01-05
TW201615208A (zh) 2016-05-01
US20150359868A1 (en) 2015-12-17
ES2558131T3 (es) 2016-02-02
US20070014844A1 (en) 2007-01-18
EP1896051A4 (en) 2008-08-27
PT1896051E (pt) 2015-01-13
PT2366400E (pt) 2016-02-02
JP2008546833A (ja) 2008-12-25
CN101309697A (zh) 2008-11-19
JP2013047234A (ja) 2013-03-07
WO2007015171A3 (en) 2007-06-14
PL2366400T3 (pl) 2016-03-31
EP2366400A1 (en) 2011-09-21
CA2613327A1 (en) 2007-02-08
BRPI0613510A2 (pt) 2011-01-11
PL1896051T3 (pl) 2015-04-30
HUE026490T2 (en) 2016-06-28
ES2526344T3 (es) 2015-01-09
JP5364371B2 (ja) 2013-12-11
CN105194650A (zh) 2015-12-30
EP1896051A2 (en) 2008-03-12
WO2007015171A2 (en) 2007-02-08
DK2366400T3 (en) 2016-01-11
TW200738253A (en) 2007-10-16
EP2366400B1 (en) 2015-09-30
TWI511738B (zh) 2015-12-11
US9119784B2 (en) 2015-09-01

Similar Documents

Publication Publication Date Title
AR054526A1 (es) Metodo para tartar pacientes con una vacuna de glicoproteina mucinosa (muc-1)
AR051350A1 (es) Vacuna de glucoproteina mucinosa (muc-1)
PE20170140A1 (es) Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer
AR107020A2 (es) Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9)
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
CY1109463T1 (el) Πεπτιδια kdr και εμβολια που τα περιλαμβανουν
CR7786A (es) Anticuerpos neutralizantes contra gdf-8 y el uso de los mismos
CY1115841T1 (el) Εμβολια πεπτιδιου παραγομενα απο epha4
ES2694667T3 (es) Método para producir oxalato oxidasas que tienen actividad óptica cerca de pH fisiológico y uso de tales oxalato oxidasas recombinantes en el tratamiento de enfermedades relacionadas con oxalato
ITMI20041550A1 (it) Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
BR0113006A (pt) Método para tratar doença de armazenamento de glicogênio tipo ii num indivìduo e seu uso
NO20055209D0 (no) Peptabody for cancerbehandling
EA201492148A1 (ru) Способ лечения немелкоклеточного рака легких
JP2015530391A (ja) 皮膚老化を予防及び／又は改善するためのｐｅｄｆ−由来ポリペプチドの使用
CY1112867T1 (el) Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια
AR112166A1 (es) Composiciones terapéuticas y métodos para el tratamiento de hepatitis b
DK2089433T3 (da) Behandling, der er rettet mod cathepsin S
ATE421330T1 (de) Flüssige allergie-impfstoffformulierung zur oromukosalen verabreichung
AR039895A1 (es) Composicion que comprende una vitamina, una sal de metal y una insulina o una hormona del crecimiento y uso de dichos componentes para prepararla
SE0401631L (sv) Ny sammansättning
AR073967A1 (es) Peptido-epitope rab6kifl/kif20a y vacunas que contienen al mismo
WO2007120555A3 (en) Assessment of heart failure risk using genetic assessment of g-protein beta-3 subunit polymorphism
ATE537838T1 (de) Kombinationstherapie mit kloretazin(tm)
ATE315406T1 (de) Semi-allogene antitumor-vakzine mit hla-haplo- identischen antigen-präsentierenden zellen

Legal Events

Date Code Title Description
FB Suspension of granting procedure